180
Participants
Start Date
November 22, 2022
Primary Completion Date
April 19, 2027
Study Completion Date
April 19, 2027
JNJ-79635322
JNJ-79635322 will be administered as SC injection.
RECRUITING
UZ Antwerpen, Edegem
RECRUITING
CHU de Liege, Liège
RECRUITING
UZ Gent, Ghent
RECRUITING
Icahn School of Medicine at Mt. Sinai, New York
RECRUITING
Memorial Sloan Kettering Cancer Center, New York
RECRUITING
University of Pennsylvania Division of Hematology Oncology Perelman Center for Advanced Medicine, Philadelphia
RECRUITING
Levine Cancer Institute, Charlotte
RECRUITING
Hosp Univ Fund Jimenez Diaz, Madrid
RECRUITING
Clinica Univ. de Navarra, Pamplona
RECRUITING
Institut Claudius Regaud, Toulouse
COMPLETED
Chu Rennes Hopital Pontchaillou, Rennes
RECRUITING
Hosp Clinico Univ de Salamanca, Salamanca
RECRUITING
CHU Nantes, Nantes
RECRUITING
CHU Lyon Sud, Pierre-Bénite
RECRUITING
MD Anderson Cancer Center, Houston
RECRUITING
Colorado Blood Cancer Institute, Denver
RECRUITING
City of Hope, Duarte
RECRUITING
City of Hope Orange County Lennar Foundation Cancer Center, Irvine
RECRUITING
University of California San Francisco, San Francisco
ACTIVE_NOT_RECRUITING
Japanese Red Cross Medical Center, Shibuya City
ACTIVE_NOT_RECRUITING
Osaka University Hospital, Suita-shi
COMPLETED
The Cancer Institute Hospital of JFCR, Tokyo
RECRUITING
VUMC Amsterdam, Amsterdam
RECRUITING
Universitair Medisch Centrum Groningen, Groningen
RECRUITING
UMC Utrecht, Utrecht
RECRUITING
Hosp. Univ. Germans Trias I Pujol, Badalona
RECRUITING
Hosp Clinic de Barcelona, Barcelona
RECRUITING
University College Hospital, London
RECRUITING
Royal Marsden Hospital, Sutton
Janssen Research & Development, LLC
INDUSTRY